Global Disopyramide Phosphate Sales Market Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Disopyramide Phosphate Sales Market Report 2024
Market Analysis and InsightsGlobal Disopyramide Phosphate Market
Disopyramide phosphate is a class I anti-arrhythmic drug used to treat cardiac arrhythmias. It interferes with the depolarization of the cardiac membrane that results in depressant action on the heart rhythm. The drug is used to treat arrhythmias and prevent paroxysmal supraventricular tachycardia.
Due to the COVID-19 pandemic, the global Disopyramide Phosphate market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Norpace accounting for % of the Disopyramide Phosphate global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
The United States Disopyramide Phosphate market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Disopyramide Phosphate include Sanofi, Merck, Teva, Santa Cruz, Mylan, Interpharm, Watson, Sandoz and Pfizer, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Disopyramide Phosphate Scope and Market Size
The global Disopyramide Phosphate market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Disopyramide Phosphate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Norpace
Rythmodan
Others
Hospital Pharmacy
Retail Pharmacy
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
Sanofi
Merck
Teva
Santa Cruz
Mylan
Interpharm
Watson
Sandoz
Pfizer
Aurolife
Disopyramide phosphate is a class I anti-arrhythmic drug used to treat cardiac arrhythmias. It interferes with the depolarization of the cardiac membrane that results in depressant action on the heart rhythm. The drug is used to treat arrhythmias and prevent paroxysmal supraventricular tachycardia.
Due to the COVID-19 pandemic, the global Disopyramide Phosphate market size is estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Norpace accounting for % of the Disopyramide Phosphate global market in 2024, is projected to value US$ million by 2034, growing at a revised % CAGR from 2023 to 2034. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
The United States Disopyramide Phosphate market is estimated at US$ million in 2024, while China was US$ million. The proportion of the United States is % in 2024, while Chinese percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period.
The global key manufacturers of Disopyramide Phosphate include Sanofi, Merck, Teva, Santa Cruz, Mylan, Interpharm, Watson, Sandoz and Pfizer, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In United States, in terms of sales revenue, in 2024, the top three players hold a share about %, while in China, top three players hold a share nearly %.
Global Disopyramide Phosphate Scope and Market Size
The global Disopyramide Phosphate market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Disopyramide Phosphate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2034.
Segment by Type
Norpace
Rythmodan
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Others
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Sanofi
Merck
Teva
Santa Cruz
Mylan
Interpharm
Watson
Sandoz
Pfizer
Aurolife